IQVIA™ Real-World Insights Bibliography

Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer
Author(s): Gomez-Ulloa D1, Amonkar M2, Kothari S3, Cheung WY4, Chau I5, Zalcberg J6, Lara N1, Falcone A7
Affiliations(s): 1 IQVIA, Barcelona, Spain 2 Merck & Co., Inc., North Wales, PA, US 3 Merck & Co., Inc., Kenilworth, NJ, US 4 British Columbia Cancer Agency, Vancouver, BC, Canada 5 Royal Marsden Hospital, London, UK 6 Alfred Health, Melbourne, Australia 7 University of Pisa, Pisa, Italy
Publication(s):  BMC Gastroenterology
BMC Gastroenterology volume 20, Article number: 133 (2020)
Document Type(s): Article,
Countries: Australia, Canada, Italy, UK,
Click here for the abstract
C:
Y:
Oncology,
2020
  L:
A:
English
Retrospective cohort analysis,
  Add to report
 
 
Real-world treatment patterns and clinical outcomes in patients receiving second-line (2L) treatment for advanced or metastatic gastric cancer (GC)
Author(s): Amonkar M1, Gomez-Ulloa D2, Smita Kothari1, Cheung WY3, Chau I4, Zalcberg JR5, Lara N2, Falcone A6
Affiliations(s): 1 Merck & Co., Inc., Kenilworth, NJ, USA 2 IQVIA, Barcelona, Spain 3 British Columbia Cancer Agency, Vancouver, BC, Canada 4 Royal Marsden Hospital, London, UK 5 Alfred Health, Melbourne, Australia 6 University of Pisa, Pisa, Italy
Publication(s):  BMC Gastroenterology volume 20, Article number: 133 (2020)
Document Type(s): Poster,
Countries: Australia, Canada, Italy, UK,
C:
Y:
Oncology,
2019
  L:
A:
English
Retrospective cohort analysis,
  Add to report
 
 
Treat and extend treatment interval patterns with anti-VEGF therapy in nAMD patients
Author(s): Skelly A1, Bezlyak V1, Liew G2, Kap E3, Sagkriotis A1
Affiliations(s): 1. Novartis Pharma AG, 4002 Basel, Switzerland; 2. Westmead Institute for Medical Research, University of Sydney, Westmead NSW 2145, Australia; 3. IQVIA Commercial GmbH & Co. OHG, 60549 Frankfurt, Germany
Publication(s): 
Document Type(s): Article,
Countries: Australia,
Click here for the abstract
C:
Y:
Ophthalmology,
2019
  L:
A:
English
clinical setting: Secondary care, Epidemiological study, Observational study, Retrospective database analysis,
  Add to report
 
 
Clinical Characteristics of 3,030 Glioblastoma Multiforme (GBM) Patients in High, Upper Middle and Lower Middle Economic Regions Based on Real-World Data (RWD)
Author(s):  Mitrofan L1 , M.R. Krukas-Hampel M.R2 , L.A. Mendoza L.A3
Affiliations(s): IQVIA, Paris, FR; IQVIA New York, US; IQVIA, Prague, CZ
Publication(s):  ESMO 2018
Document Type(s): Poster,
Countries: Australia, Brazil, Canada, France, Germany, Italy, Mexico, Spain, Taiwan, UK,
C:
Y:
Oncology,
2018
  L:
A:
English
  Add to report
 
 
Clinical characteristics of Glioblastoma Multiforme (GBM) Patients Who Reached 400 Days Post Diagnostic from a Retrospective Real-World Data
Author(s):  Mitrofan L.M.1,Krukas-Hampel M.R.2, Mendoza L.A.3
Affiliations(s): 1 IQVIA, Paris, FR; 2IQVIA New York, US; 3IQVIA, Prague, CZ
Publication(s):  ESMO 2018
Document Type(s): Poster,
Countries: Australia, Brazil, Canada, France, Germany, Italy, Mexico, Spain, Taiwan, UK,
C:
Y:
Oncology,
2018
  L:
A:
English
  Add to report
 
 
Identifying the confuonders that explain the difference in readouts between non-interventional and randomized controlled trials: the case of treatments in neovascular age-related macular degeneration
Author(s): Sakriotis A1, Griner R2, Durus A1, Doyle OM2, Rodriguez-Torres L1, Wintermantel T2, Clemens A13
Affiliations(s): 1. Novartis Pharma AG, Basel, Switzerland; 2. IQVIA Real World Insights, Switzerland/UK/US; 3. Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany
Publication(s):  ISPOR Europe, Barcelona, Spain, 10-14 November 2018
Document Type(s): Poster,
Countries: Australia, UK, USA,
C:
Y:
Ophthalmology,
2018
  L:
A:
English
clinical setting: Secondary care, Epidemiological study, Observational study, Retrospective database analysis,
  Add to report
 
 
Direct and Indirect Protection with Pediatric Quadrivalent Live-Attenuated Influenza Vaccination in Europe Estimated by a Dynamic Transmission Model
Author(s): Gerlier L1, Hackett J2, Lawson R2, Dos Santos Mendes S3, Weil-Olivier C4, Schwehm M5, Eichner M6,7
Affiliations(s): 1 QuintilesIMS, Real-World Evidence Solutions, Zaventem, Belgium 2 AstraZeneca, Gaithersburg, MD, USA 3 AstraZeneca, Brussels, Belgium (Current affiliation: MSD, Brussels, Belgium) 4 Department of Pediatrics, University Paris VII, Paris, France 5 ExploSYS GmbH, Leinfelden-Echterdingen, Germany 6 Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen, Germany 7 Epimos GmbH, Dusslingen, Germany
Publication(s):  JHEOR 2017;5(1):89-108
Document Type(s): Article,
Countries: Australia, Belgium, Finland, France, Germany, Greece, Italy, Luxembourg, Netherlands, Poland, Portugal, Spain, Sweden, UK,
C:
Y:
Immunology and Vaccination, Infectious disease, Respiratory disease,
2017
  L:
A:
English
Epidemiological study, Public Health,
  Add to report
 
 
HEALTH-ECONOMICS EVALUATIONS IN FRANCE, ENGLAND, CANADA AND AUTRALIA: COMPARISON OF METHODOLOGIES AND IMPACT ON DRUGS
Author(s): Bucher D*, Abalan M-E*, Allou A*, Dumon L*, Vialard L *, Troubat A*, Maurel F*
Affiliations(s): IQVIA France - RWI
Publication(s):  ISPOR 2017
Document Type(s): Poster,
Countries: Australia, Canada, France, UK,
C:
Y:
Comparative Effectiveness & Health Technology Assessment,
2017
  L:
A:
English
Cost effectiveness, Literature Review, Pricing & Reimbursement, Review,
  Add to report
 
 
A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom.
Author(s): Johnston RL1,2, Carius HJ3, Skelly A4, Ferreira A5, Milnes F4, Mitchell P6.
Affiliations(s): 1 The Royal College of Ophthalmologists' National Ophthalmology Database, London, UK. 2 Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, UK. 3 QuintilesIMS, Frankfurt am Main, Germany. 4 Novartis Pharma AG, Basel, Switzerland. 5 Novartis Pharma AG, Basel, Switzerland. alberto.ferreira@novartis.com. 6 Department of Ophthalmology, Westmead Millennium Institute, University of Sydney, Westmead, NSW, Australia.
Publication(s):  Advances in therapy
Document Type(s): Article,
Countries: Australia, UK,
Click here for the abstract
C:
Y:
Ophthalmology,
2017
  L:
A:
English
Retrospective cohort analysis,
  Add to report
 
 
Drug Utilization Study for Lisdexamfetamine Dimesylate (LDX) in Australia
Author(s): von Bredow D1, Ehlken B1, Blumentals WA2, Kolb N1, Keja J1, Maxwell T2
Affiliations(s): 1 IMS HealthGmbH & Co. OHG, Munich, Germany, 1 Shire Pharmaceuticals, Lexington, MA, USA
Publication(s):  32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)
Document Type(s): 
Countries: Australia,
C:
Y:
Drug Utlization Study,
2016
  L:
A:
English
Database Study, Survey research,
  Add to report
 
 
 1 of 5 Next Page Last Page